Study of Tissue Samples From Patients With Glioma or Other Brain Tumors

Identification of Genes Involved in the Pathogenesis of Gliomas by Transcriptome Analysis

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00967200

Enrollment

180

Registered

2009-08-27

Start date

2003-11-30

Completion date

2015-11-30

Last updated

2015-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Central Nervous System Lymphoma

Keywords

adult anaplastic astrocytoma, adult diffuse astrocytoma, adult glioblastoma, adult giant cell glioblastoma, adult gliosarcoma, adult pilocytic astrocytoma, adult pineal gland astrocytoma, adult subependymal giant cell astrocytoma, adult brain stem glioma, adult choroid plexus tumor, adult craniopharyngioma, adult ependymoblastoma, adult medulloblastoma, adult supratentorial primitive neuroectodermal tumor (PNET), adult anaplastic ependymoma, adult ependymoma, adult myxopapillary ependymoma, adult subependymoma, meningeal melanocytoma, adult meningeal hemangiopericytoma, adult grade I meningioma, adult grade II meningioma, adult anaplastic meningioma, adult papillary meningioma, adult anaplastic oligodendroglioma, adult oligodendroglioma, adult pineoblastoma, adult pineocytoma, adult mixed glioma, recurrent adult brain tumor

Brief summary

RATIONALE: Studying the genes expressed in samples of tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors predict how patients will respond to treatment. PURPOSE: This research study is looking at tissue samples from patients with glioma or other brain tumors.

Detailed description

OBJECTIVES: Primary * To better understand the pathophysiology of gliomas and identify molecular markers that may predict prognosis and progression or that could identify new therapeutic approaches. Secondary * To compare gene expression profiles, in terms of response to treatment, and attempt to isolate subgroups of patients with objective response to certain types of chemotherapy or radiotherapy. OUTLINE: This is a multicenter study. Biological samples are collected from patients at time of surgery for diagnostic and/or treatment purposes.

Interventions

OTHERpharmacogenomic studies

pharmacogenomic studies

OTHERlaboratory biomarker analysis

laboratory biomarker analysis

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 120 Years

Healthy volunteers

Inclusion criteria

Inclusion Histologically confirmed glioma of any grade or rare primary brain tumor No urgent situation No known or suspected active infection Must not be deprived of liberty or protected by law Not pregnant or nursing Exclusion : No concurrent participation in other trials that require a period of exclusion

Design outcomes

Primary

Measure	Time frame	Description
Pathophysiology of gliomas	1 day	Pathophysiology of gliomas that may predict prognosis and progression or that could identify new therapeutic

Secondary

Measure	Time frame	Description
Identification of molecular	1 day	Identification of molecular markers that may predict prognosis and progression or that could identify new therapeutic

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026